Literature DB >> 16848866

The international immune tolerance study: a multicenter prospective randomized trial in progress.

D M Dimichele, C R M Hay.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16848866     DOI： 10.1111/j.1538-7836.2006.02127.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  16 in total

Review 1.  Barriers to primary prophylaxis in haemophilic children: the issue of the venous access.

Authors:  Elena Santagostino; Maria Elisa Mancuso
Journal:  Blood Transfus       Date:  2008-09       Impact factor: 3.443

Review 2.  Immune tolerance induction for patients with severe hemophilia A: a critical literature review.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  J Thromb Thrombolysis       Date:  2011-11       Impact factor: 2.300

3.  Risk factors for inhibitor formation in haemophilia: a prevalent case-control study.

Authors:  M V Ragni; O Ojeifo; J Feng; J Yan; K A Hill; S S Sommer; M N Trucco; D J Brambilla
Journal:  Haemophilia       Date:  2009-06-26       Impact factor: 4.287

4.  The International Immune Tolerance Induction Study and its follow-up study on Japanese hemophilia A patients with inhibitors.

Authors:  Akira Yoshioka; Eizaburo Ishii; Tamaki Ueno; Ikuya Usami; Masao Kobayashi; Ryoji Kobayashi; Manabu Sotomatsu; Akira Shirahata; Takashi Suzuki; Masashi Taki; Yasushi Ishida; Tadashi Matsushita; Midori Shima; Keiji Nogami; Michio Sakai; Hisato Kigasawa; Katsuyuki Fukutake
Journal:  Int J Hematol       Date:  2015-02-18       Impact factor: 2.490

5.  Emicizumab should be prescribed independent of immune tolerance induction.

Authors:  Sandra Le Quellec; Claude Negrier
Journal:  Blood Adv       Date:  2018-10-23

Review 6.  Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

Review 7.  Management of haemophilia A-inhibitor patients: clinical and regulatory perspectives.

Authors:  Zera Tellier; Marie-Hélène André; Benoît Polack
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

8.  Improved treatment feasibility in children with hemophilia using arteriovenous fistulae: the results after seven years of follow-up.

Authors:  Maria Elisa Mancuso; Luisa Berardinelli; Claudio Beretta; Mauro Raiteri; Ermanno Pozzoli; Elena Santagostino
Journal:  Haematologica       Date:  2009-03-13       Impact factor: 9.941

Review 9.  Octocog alfa, antihaemophilic factor (recombinant), plasma/albumin free method (Advate®): a review of its use in the management of patients with haemophilia A.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2012-05-07       Impact factor: 9.546

Review 10.  Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B.

Authors:  Abha H Athale; Maura Marcucci; Alfonso Iorio
Journal:  Cochrane Database Syst Rev       Date:  2014-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.